Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Antiviral agents

Government tightens availability of remdesivir treatment for COVID-19 patients as supplies shrink

Owing to a rise in COVID-19 hospitalisations, the Department for Health and Social Care has enforced extra rules on remdesivir treatment to counter the “increased demand against available supply”.

Open access article

The Royal Pharmaceutical Society has made this article free to access in order to help healthcare professionals stay informed about an issue of national importance.

To learn more about coronavirus, please visit:

Remdesivir bottles


The supply disruption alert from the Department for Health and Social Care has asked that clinicians prescribe a maximum five-day course of remdesivir, instead of a treatment course of up to ten days as was previously advised

Patients with COVID-19 across the UK will now have to meet additional criteria before being prescribed remdesivir as supplies of the drug become limited.

The additional requirements will mean patients who are on mechanical ventilation or extracorporeal membrane oxygenation will not be considered for treatment with remdesivir.

The criteria were initially set out in guidance published on 3 September 2020, but were said to be “only applicable should demand for remdesivir exceed supply”.

The Department of Health and Social Care (DHSC) announced plans to enforce the extra rules in a supply disruption alert published on 29 September 2020.

It said clinicians should now adhere to the additional criteria as the treatment had seen “increased demand against available supply” in recent weeks.

The latest alert has also requested that clinicians prescribe “a maximum treatment course of five days”, which is half the maximum treatment length initially suggested when remdesivir was first approved for use against COVID-19 in July 2020.

However, a recent study suggested that there is no significant difference in efficacy between five-day and ten-day courses of the drug in patients with severe COVID-19.

The alert also asks trusts to share information on their stock of remdesivir with regional procurement pharmacy leads.

“A percentage of stock will be held centrally to support allocation to areas of greatest need, using the principles of mutual aid,” it says.

A spokesperson for the DHSC told The Pharmaceutical Journal that it is “aware of a rise in the use of remdesivir in line with a rise in COVID-19 hospital cases”.

“While supplies of remdesivir continue to increase, we have asked the NHS to temporarily prioritise patients to ensure those most likely to benefit can access it.

“Patients are also receiving other approved treatments; for example, dexamethasone or hydrocortisone, which have been proven to save lives and are in good supply.”

The DHSC added that it was expecting further supplies of remdesivir towards the end of October 2020 and it anticipated that the additional criteria will only be in place for a matter of weeks, subject to levels of hospitalisation.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208410

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.